The New York Times - Business:
The health care giant’s David Ricks defended the agency’s role in reviewing data and ensuring drug safety.
This post first appeared in The New York Times - Business. Read the original article.
Eli Lilly Chief Says He Will Fight for the FDA, Challenging RFK Jr.’s Stance
